Valeant Pharmaceutical (VRX) Reports Q2 Earnings of $0.73; Raises FY11 EPS Outlook
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q2 EPS of $0.73, versus $0.60 reported last year. Revenue for the quarter came in at $609 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.